Hypothesis

Aged B cells exhibit reduced AID and E47 expression, which not only diminishes antibody affinity and class switching but also sustains a pathogenic state characterized by elevated MHC‑II surface presentation and insulin‑receptor‑dependent signaling. Restoring AID/E47 levels in aged B cells will normalize DNA repair dynamics, lower maladaptive MHC‑II–mediated CD4 T cell help, and consequently attenuate T cell senescence and clonal restriction.

Mechanistic Basis

1. AID loss → defective DNA repair → chronic DNA damage signaling – In aged B cells, diminished AID reduces the generation of controlled DNA breaks during somatic hypermutation, shifting repair toward error‑prone pathways that activate ATM/Chk2 and NF‑κB. This sustains a transcriptional program that up‑regulates MHC‑II and co‑stimulatory molecules (CD80/86) independent of antigenic stimulation AID transcription decreases substantially with aging.
2. E47 decline → impaired class‑switch recombination → persistent IgM secretion – Lower E47 mRNA stability curtails germline transcription at switch loci, biasing aged B cells toward IgM secretion and prolonging their residence in germinal center–like niches where they repeatedly engage CD4 T cells E47 mRNA stability declines, impairing isotype switching in aged B‑2 cells.
3. Insulin‑receptor signaling in B cells amplifies MHC‑II presentation – Hyperactive insulin‑receptor signaling in aged B cells enhances antigen processing and MHC‑II loading, a state that is further reinforced by the DNA damage‑induced NF‑κB milieu B cell‑intrinsic insulin receptor signaling influencing age‑related B cell phenotypes that induce CD4 T cell dysfunction, partly driven by MHC class II.
4. Sex‑biased DNA repair efficiency – Older males display a larger fold‑reduction in Phase II SHM DNA repair activities, predicting a stronger MHC‑II–driven pro‑senescent signal in male‑derived B cells altered DNA repair pathways, with older males showing decreased frequency of Phase II SHM DNA repair activities.

Predictions

• In vitro: Transducing aged murine B cells with lentiviral vectors expressing AID and E47 will decrease surface MHC‑II (mean fluorescence intensity ↓ ≥ 30 %) and reduce insulin‑receptor‑phosphorylation levels compared with vector‑only controls.
• Co‑culture: Naïve CD4 T cells co‑cultured with AID/E47‑rescued aged B cells will show diminished up‑regulation of senescence markers (p16^INK4a, SA‑β‑gal) and retain a more diverse TCR repertoire (Shannon entropy ↑ ≥ 0.5 units) relative to T cells cultured with untreated aged B cells.
• In vivo: Adoptive transfer of AID/E47‑expressing aged B cells into aged wild‑type mice will lead to a reduction in the frequency of PD‑1^hi TCF‑1^lo senescent CD4 T cells in spleen and lymph nodes (≥ 20 % decrease) and improve serum IgG affinity (ELISA avidity index ↑ ≥ 1.5‑fold) after immunization with a T‑dependent antigen.
• Sex difference: Male mice will exhibit a greater magnitude of MHC‑II reduction and T cell senescence rescue than female mice following the same intervention, reflecting the baseline sex bias in DNA repair.

Experimental Approaches

• Genetic rescue: Use CRISPR‑activation (CRISPRa) or lentiviral overexpression to elevate AID and E47 specifically in B cells isolated from 20‑month‑old mice; confirm expression by qPCR and Western blot.
• Flow cytometry: Quantify MHC‑II (I‑A/I‑E), CD80, CD86, and phosphorylated insulin‑receptor (Tyr1150/1151) on B cells before and after rescue.
• Functional assays: Measure class‑switch recombination (IgG1 ELISA after LPS/IL‑4 stimulation) and somatic hypermutation frequency (sequencing of IgV genes).
• T cell readouts: Co‑culture sorted B cells with CFSE‑labeled naïve OT‑II CD4 T cells; assess proliferation, senescence (p16, γH2AX), and TCR diversity by spectratyping or immunostaining.
• In vivo validation: Transfer rescued or control B cells into aged recipients; immunize with NP‑OVA in alum; track germinal center dynamics, antibody affinity maturation, and CD4 T cell phenotypes over 4 weeks.

If AID/E47 restoration fails to lower MHC‑II or improve T cell senescence, the hypothesis would be falsified, indicating that the pro‑aging influence of aged B cells operates independently of these DNA‑modifying enzymes and requires alternative therapeutic targeting.